跳转至内容
Merck

N8288

Sigma-Aldrich

Anti-NLK (441-455) antibody produced in rabbit

IgG fraction of antiserum, buffered aqueous solution

别名:

Anti-nemo-like kinase (Homo sapiens)

登录查看公司和协议定价


About This Item

分類程式碼代碼:
12352203
共軛:
unconjugated
application:
WB
無性繁殖:
polyclonal
物種活性:
human
citations:
2
技術:
western blot: 1:500-1:2,000

生物源

rabbit

品質等級

共軛

unconjugated

抗體表格

IgG fraction of antiserum

抗體產品種類

primary antibodies

無性繁殖

polyclonal

形狀

buffered aqueous solution

分子量

antigen ~58 kDa

物種活性

human

技術

western blot: 1:500-1:2,000

UniProt登錄號

運輸包裝

dry ice

儲存溫度

−20°C

目標翻譯後修改

unmodified

基因資訊

human ... NLK(51701)

免疫原

synthetic peptide corresponding to amino acids 441-455 of human NLK.

應用

Yale Center for High Throughput Cell Biology IF-tested antibodies. Each antibody is tested by immunofluorescence against HUVEC cells using the Yale HTCB IF protocol. To learn more about us and Yale Center for High Throughput Cell Biology partnership, visit sigma.com/htcb-if.

外觀

0.01M 磷酸缓冲盐溶液,pH 7.4,含 15mM 叠氮化钠。

免責聲明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

未找到合适的产品?  

试试我们的产品选型工具.


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Sungho Moon et al.
EMBO reports, 18(1), 61-71 (2016-12-17)
Hippo signaling controls organ size by regulating cell proliferation and apoptosis. Yes-associated protein (YAP) is a key downstream effector of Hippo signaling, and LATS-mediated phosphorylation of YAP at Ser127 inhibits its nuclear localization and transcriptional activity. Here, we report that
Xian Wang et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(9), 2648-2662 (2021-02-06)
Endocrine resistance remains a major clinical challenge in estrogen receptor (ER)-positive breast cancer. Despite the encouraging results from clinical trials for the drugs targeting known survival signaling, relapse is still inevitable. There is an unmet need to discover new drug

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门